413 related articles for article (PubMed ID: 28816138)
1. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count.
Xie X; Gong S; Jin H; Yang P; Xu T; Cai Y; Guo C; Zhang R; Lou F; Yang W; Wang H
Radiat Oncol; 2020 Mar; 15(1):65. PubMed ID: 32169088
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Francis SR; Orton A; Thorpe C; Stoddard G; Lloyd S; Anker CJ
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):884-894. PubMed ID: 28864404
[TBL] [Abstract][Full Text] [Related]
4. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
5. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
Fang P; Jiang W; Davuluri R; Xu C; Krishnan S; Mohan R; Koong AC; Hsu CC; Lin SH
Radiother Oncol; 2018 Sep; 128(3):584-590. PubMed ID: 29530432
[TBL] [Abstract][Full Text] [Related]
6. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
Deng W; Xu C; Liu A; van Rossum PSN; Deng W; Liao Z; Koong AC; Mohan R; Lin SH
Radiother Oncol; 2019 Apr; 133():9-15. PubMed ID: 30935587
[TBL] [Abstract][Full Text] [Related]
7. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
9. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
[TBL] [Abstract][Full Text] [Related]
10. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
11. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
[TBL] [Abstract][Full Text] [Related]
13. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.
Defoe SG; Pennathur A; Flickinger JC; Heron DE; Gibson MK; Luketich JD; Greenberger JS
Am J Clin Oncol; 2011 Dec; 34(6):587-92. PubMed ID: 22101387
[TBL] [Abstract][Full Text] [Related]
14. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
de Vos-Geelen J; Hoebers FJP; Geurts SME; Hoeben A; de Greef BTA; Voncken FEM; Bogers JHA; Braam PM; Muijs CKT; de Jong MA; Kasperts N; Rozema T; Jeene PM; Blom GJ; van Dieren JM; Hulshof MCCM; van Laarhoven HWM; Grabsch HI; Lemmens VEPP; Tjan-Heijnen VCG; Nieuwenhuijzen GAP
Acta Oncol; 2020 Aug; 59(8):895-903. PubMed ID: 32319845
[No Abstract] [Full Text] [Related]
15. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
[TBL] [Abstract][Full Text] [Related]
16. Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.
Xu H; Lin M; Hu Y; Zhang L; Li Q; Zhu J; Wang S; Xi M
Oncologist; 2021 Mar; 26(3):e425-e434. PubMed ID: 32960471
[TBL] [Abstract][Full Text] [Related]
17. Management of locoregional stage esophageal cancer: a single center experience.
Javle MM; Nwogu CE; Donohue KA; Iyer RV; Brady WE; Khemka SV; Smith JL; Demmy TL; Yang GY; Nava HR
Dis Esophagus; 2006; 19(2):78-83. PubMed ID: 16643174
[TBL] [Abstract][Full Text] [Related]
18. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
19. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
20. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.
Kim HJ; Suh YG; Lee YC; Lee SK; Shin SK; Cho BC; Lee CG
Cancer Res Treat; 2017 Jul; 49(3):669-677. PubMed ID: 27737537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
